Influence of potential inhalation carriers on stability of thymopentin in rat bronchoalveolar lavage fluid
Authors:
- Cuifang CaiCCCuifang Cai
- Lei WangLWLei Wang
- Wenna DongWDWenna Dong
- Xing TangXTXing Tang
- 8 January 2014
- journal article
- Published by Taylor & Francis in Drug Delivery
- Vol. 21 (6) , 495-500
Abstract
In the present study, the stability of thymopentin (TP5) in bronchoalveolar lavage fluid (BALF) in presence of potential excipients in inhalation formulation was investigated. The content of TP5 was determined using HPLC method. Commonly used bulking agent, dispersibility enhancers and absorption enhancers in inhalation were investigated with respect to the stability of TP5 in BALF. Finally, the stability of TP5 in two inhalation formulations based on the screening experiments was tested in BALF. The results showed that TP5 alone degraded very rapidly in BALF and zero-order enzymatic reaction with a half-life of t0.5 = 49.20 min was observed using 10 times diluted BALF. Among the amino acids examined, leucine and phenylalanine effectively inhibited the enzymolysis of TP5 with prolonged half-life of 112.7 min and 136.2 min, respectively. Nevertheless, slight but insignificant inhibition effect was witnessed for tyrosine, aspartic acid, and lysine; and negligible prevention on the degradation process of TP5 were found for lactose and mannitol. Regarding chitosan, irrespective with molecular weight, the formation of chitosan-TP5 complex improved the stability of TP5 with prolonged t0.5 by 1.8 times. However, along with the improved stability of TP5 in spray-dried chitosan microspheres, the content of TP5 in formulations was reduced to about 75% during preparation process. Thus, leucine was proved to be a prior candidate for inhalation formulation of TP5. Consequently, the results indicate the potential of leucine as carrier for pulmonary delivery of TP5 serving as both stabilizer and dispersibility enhancer.Keywords
This publication has 17 references indexed in Scilit:
- Nanocarriers for Pulmonary Administration of Peptides and Therapeutic ProteinsNanomedicine, 2010
- Inhalable Microparticles as Carriers for Pulmonary Delivery of Thymopentin-Loaded Solid Lipid NanoparticlesPharmaceutical Research, 2010
- Dry powder inhalations containing thymopentin and its immunomodulating effects in Wistar ratsEuropean Journal of Pharmaceutical Sciences, 2009
- Chitosan-based spray-dried respirable powders for sustained delivery of terbutaline sulfateEuropean Journal of Pharmaceutics and Biopharmaceutics, 2008
- Spray-Dried Powders for Pulmonary Drug DeliveryCritical Reviews™ in Therapeutic Drug Carrier Systems, 2007
- In situ coating—An approach for particle modification and encapsulation of proteins during spray-dryingInternational Journal of Pharmaceutics, 2006
- Optimization of Formulation Components and Characterization of Large Respirable Powders Containing High Therapeutic PayloadPharmaceutical Development and Technology, 2006
- The influence of formulation components on the aerosolisation properties of spray-dried powdersJournal of Controlled Release, 2005
- The use of amino acids to enhance the aerosolisation of spray‐dried powders for pulmonary gene therapyThe Journal of Gene Medicine, 2004
- Surface Composition of Spray-Dried Particles of Bovine Serum Albumin/Trehalose/SurfactantPharmaceutical Research, 2000